IGNITE4: Results of a phase 3, randomized, multicenter, prospective trial of eravacycline vs meropenem in the treatment of complicated intraabdominal infections

Clinical Infectious Diseases

Volumn 69, Issue 6, 2019, Pages 921-929

  Solomkin, Joseph S ^a   Gardovskis, Janis ^b   Lawrence, Kenneth ^c   Montravers, Philippe ^d,e,f   Sway, Angie ^g   Evans, David ^h   Tsai, Larry ^c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b RIGA STRADINS UNIVERSITY   (Latvia)

^c Tetraphase Pharmaceuticals   (United States)

^d BICHAT HOSPITAL   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f INSERM   (France)

^g World Surgical Infection Society   (United States)

^h THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

complicated intraabdominal infection; Enterobacteriaceae; eravacycline; gram negative bacteria; multidrug resistance

Indexed keywords

ERAVACYCLINE; MEROPENEM; ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ABSCESS; ADULT; AGED; ANEMIA; ANTIBIOTIC THERAPY; APPENDICITIS; ARTICLE; CHOLECYSTITIS; CITROBACTER FREUNDII; CONTROLLED STUDY; DIARRHEA; DIVERTICULITIS; DRUG SAFETY; DRUG WITHDRAWAL; DUODENUM PERFORATION; ENTEROBACTER ASBURIAE; ENTEROBACTER CLOACAE; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; HOSPITAL PATIENT; HUMAN; HYPERTENSION; HYPOKALEMIA; INFECTION COMPLICATION; INFUSION RELATED REACTION; INTENTION TO TREAT ANALYSIS; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NONHUMAN; OUTCOME ASSESSMENT; PERITONITIS; PHASE 3 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SERRATIA MARCESCENS; SMALL INTESTINE PERFORATION; STOMACH PERFORATION; THROMBOSIS; VOMITING; WOUND INFECTION; CLINICAL TRIAL; COMPLICATION; DISEASE MANAGEMENT; MICROBIOLOGY; TIME TO TREATMENT; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; DISEASE MANAGEMENT; FEMALE; HUMANS; INTRAABDOMINAL INFECTIONS; MALE; MEROPENEM; TETRACYCLINES; TIME-TO-TREATMENT; TREATMENT OUTCOME;

EID: 85067055105     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciy1029     Document Type: Article

References (45)

1. Antimicrobial resistance threats in the United States, 2013. 2013. Available at: httpos://www. cdc. gov/drugresistance/pdf/ar-threats-2013-508. pdf. Accessed 14 November 2018.
2. Antimicrobial resistance. 2018. Available at: https://ecdc. europa. eu/en/antimicrobial-resistance. Accessed 14 November 2018.
3. Antimicrobial resistance. 2018. Available at: https://www. idsociety. org/public-health/antimicrobial-resistance/antimicrobial-resistance/. Accessed 14 November 2018.
4. Antimicrobial resistance. 2018. Available at: http://www. who. int/antimicrobial-resistance/en/. Accessed 14 November 2018.
5. Chong Y, Shimoda S, Shimono N. Current epidemiology, genetic evolution and clinical impact of extended-spectrum ?-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Infect Genet Evol 2018; 61:185-8.
6. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60:913-20.
7. Thabit AK, Crandon JL, Nicolau DP. Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials. Expert Opin Pharmacother 2015; 16:159-77.
8. Logan LK, Weinstein RA. The epidemiology of carbapenem-resistant Enterobacteriaceae: the impact and evolution of a global menace. J Infect Dis 2017; 215:28-36.
9. Rodriguez-Bano J, Gutierrez-Gutierrez B, Machuca I, Pascual A. Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing enterobacteriaceae. Clinical Microbiology Reviews 2018; 31.
10. Harris P TP, David Lye D, Mo Y. The MERINO trial: piperacillin-tazobactam versus meropenem for the definitive treatment of bloodstream infections caused by third-generation cephalosporin nonsusceptible Escherichia coli or Klebsiella spp.: an international multi-centre open label non-inferiority randomised controlled trial. Madrid: European Congress of Clinical Microbiology and Infectious Diseases, 2018.
11. Frere JM, Sauvage E, Kerff F. From "An Enzyme Able to Destroy Penicillin" to carbapenemases: 70 years of beta-lactamase misbehaviour. Curr Drug Targets 2016; 17:974-82.
12. Molton JS, Tambyah PA, Ang BS, Ling ML, Fisher DA. The global spread of healthcare-associated multidrug-resistant bacteria: a perspective from Asia. Clin Infect Dis 2013; 56:1310-8.
13. Yang Q, Xu YC, Kiratisin P, Dowzicky MJ. Antimicrobial activity among gram-positive and gram-negative organisms collected from the Asia-Pacific region as part of the tigecycline evaluation and surveillance trial: comparison of 2015 results with previous years. Diagn Microbiol Infect Dis 2017; 89:314-23.
14. Pfaller MA, Huband MD, Streit JM, Flamm RK, Sader HS. Surveillance of tigecycline activity tested against clinical isolates from a global (North America, Europe, Latin America and Asia-Pacific) collection (2016). Int J Antimicrob Agents 2018; 51:848-53.
15. Lob SH, Biedenbach DJ, Badal RE, Kazmierczak KM, Sahm DF. Antimicrobial resistance and resistance mechanisms of Enterobacteriaceae in ICU and non-ICU wards in Europe and North America: SMART 2011-2013. J Glob Antimicrob Resist 2015; 3:190-7.
16. Jean SS, Hsueh PR; SMART Asia-Pacific Group. Distribution of ESBLs, AmpC ?-lactamases and carbapenemases among Enterobacteriaceae isolates causing intra-abdominal and urinary tract infections in the Asia-Pacific region during 2008-14: results from the study for monitoring antimicrobial resistance trends (SMART). J Antimicrob Chemother 2017; 72:166-71.
17. van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence 2017; 8:460-9.
18. Tracking CRE. 2016. Available at: https://www. cdc. gov/hai/organisms/cre/ TrackingCRE. html. Accessed 24 June 2018.
19. Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs 2014; 74:1315-33.
20. van Harten RM, Willems RJL, Martin NI, Hendrickx APA. Multidrug-resistant enterococcal infections: new compounds, novel antimicrobial therapies? Trends Microbiol 2017; 25:467-79.
21. Mazuski JE, Solomkin JS. Intra-abdominal infections. Surg Clin North Am 2009; 89:421-37, ix.
22. Mazuski JE, Tessier JM, May AK, et al. The Surgical Infection Society revised guidelines on the management of intra-abdominal infection. Surg Infect (Larchmt) 2017; 18:1-76.
23. Solomkin JS, Mazuski JE, Bradley JS, et al. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:133-64.
24. Chukwudi CU. rRNA binding sites and the molecular mechanism of action of the tetracyclines. Antimicrob Agents Chemother 2016; 60:4433-41.
25. Grossman TH, Starosta AL, Fyfe C, et al. Target-and resistance-based mechanistic studies with TP-434, a novel fluorocycline antibiotic. Antimicrob Agents Chemother 2012; 56:2559-64.
26. Zhang Y, Lin X, Bush K. In vitro susceptibility of ?-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE) to eravacycline. J Antibiot (Tokyo) 2016; 69:600-4.
27. Seifert H, Stefanik D, Sutcliffe JA, Higgins PG. In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii. Int J Antimicrob Agents 2018; 51:62-4.
28. Zhanel GG, Baxter MR, Adam HJ, Sutcliffe J, Karlowsky JA. In vitro activity of eravacycline against 2213 gram-negative and 2424 gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD Surveillance Study 2014-2015. Diagn Microbiol Infect Dis 2018; 91:55-62.
29. Newman JV, Zhou J, Izmailyan S, Tsai L. Randomized, double-blind, placebo-controlled studies of the safety and pharmacokinetics of single and multiple ascending doses of eravacycline. Antimicrob Agents Chemother 2018; 62.
30. Solomkin JS, Ramesh MK, Cesnauskas G, et al. Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections. Antimicrob Agents Chemother 2014; 58:1847-54.
31. Schein M, Marshall J. Source control for surgical infections. World J Surg 2004; 28:638-45.
32. Solomkin J, Hershberger E, Miller B, et al. Ceftolozane/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI). Clin Infect Dis 2015; 60:1462-71.
33. Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis 2016; 62:1380-9.
34. Solomkin J, Evans D, Slepavicius A, et al. Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE 1) Trial: a randomized clinical trial. JAMA Surg 2017; 152:224-32.
35. Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection-results from a randomized, controlled, double-blind, phase 3 program. Clin Infect Dis 2016; 62:1380-89.
36. Berne TV, Yellin AW, Appleman MD, Heseltine PN. Antibiotic management of surgically treated gangrenous or perforated appendicitis. Comparison of gentamicin and clindamycin versus cefamandole versus cefoperazone. Am J Surg 1982; 144:8-13.
37. Heseltine PN, Yellin AE, Appleman MD, et al. Perforated and gangrenous appendicitis: an analysis of antibiotic failures. J Infect Dis 1983; 148:322-9.
38. Vardakas KZ, Tansarli GS, Rafailidis PI, Falagas ME. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum ?-lactamases: a systematic review and meta-analysis. J Antimicrob Chemother 2012; 67:2793-803.
39. Girometti N, Lewis RE, Giannella M, et al. Klebsiella pneumoniae bloodstream infection: epidemiology and impact of inappropriate empirical therapy. Medicine (Baltimore) 2014; 93:298-309.
40. Harris PNA, Tambyah PA, Lye DC, et al; MERINO Trial Investigators and the Australasian Society for Infectious Disease Clinical Research Network. Effect of piperacillin-tazobactam vs meropenem on 30-day mortality for patients with E. coli or Klebsiella pneumoniae bloodstream infection and ceftriaxone resistance: a randomized clinical trial. JAMA 2018; 320:984-94.
41. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E; Tigecycline 301 Study Group; Tigecycline 306 Study Group. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin Infect Dis 2005; 41 (Suppl 5):S354-67.
42. Lauf L, Ozsvar Z, Mitha I, et al. Phase 3 study comparing tigecycline and ertapenem in patients with diabetic foot infections with and without osteomyelitis. Diagn Microbiol Infect Dis 2014; 78:469-80.
43. Matthews P, Alpert M, Rahav G, et al; Tigecycline 900 cSSSI Study Group. A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections. BMC Infect Dis 2012; 12:297.
44. O'Riordan W, Mehra P, Manos P, Kingsley J, Lawrence L, Cammarata S. A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. Int J Infect Dis 2015; 30:67-73.
45. Towfigh S, Pasternak J, Poirier A, Leister H, Babinchak T. A multicentre, open-label, randomized comparative study of tigecycline versus ceftriaxone sodium plus metronidazole for the treatment of hospitalized subjects with complicated intra-abdominal infections. Clin Microbiol Infect 2010; 16:1274-81.